Previous 10 | Next 10 |
-- Terms approved to proceed with collaborative effort with international consortium MIRAMAR, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) today announced that the company has...
Dividends officially paid on Monday, February 24, 2020 ° Ex-Dividend Date does not apply to NuGenerex Immuno-Oncology shares MIRAMAR, Fla., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex”) today cla...
Dividends officially to be paid on Monday, February 24, 2020 • Shareholders to receive 2 to 5 stock dividend of Generex Biotechnology shares plus an additional 2 to 5 stock dividend of NuGenerex Immuno-Oncology shares Ex-Date will be February 25, 2020 MIRAMAR, Fla., Feb. 2...
MIRAMAR, Fla., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for the upcoming investor conference call on Thursday February 13th 2020 at 11:00am AM Eastern time. The access information for the investor c...
MIRAMAR, Fla., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) today announced that Joe Moscato, President & Chief Executive Officer and the team from NuGenerex Immuno-Oncology will hold an investor conference call on Thursday Febr...
PAY DATE: Monday, February 24, 2020 EX DATE: Tuesday, February 25, 2020 MIRAMAR, Fla., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex”) is pleased to announce the successful completion of the FINRA review proce...
Awaiting completion of FINRA approval process Dividends remain the same Shareholders to receive 2 to 5 stock dividend of Generex Biotechnology shares plus an additional 2 to 5 stock dividend of NuGenerex Immuno-Oncology shares MIRAMAR, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Gener...
Phoenix, Arizona--(Newsfile Corp. - February 6, 2020) - The Stock Day Podcast welcomed Generex Biotechnology (OTCQB: GNBT) ("the Company"), an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapie...
NuGenerex Immuno-Oncology’s Ii-Key technology is clinically proven to activate the immune system against numerous viruses including H5N1 avian influenza virus Ii-Key peptide vaccines offer real potential for a cost effective, rapid response vaccine that can provide immunit...
MIRAMAR, Fla., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) is proud to announce the appointment of Dr. Carol Nacy, PhD to the NuGenerex Immuno-Oncology (NGIO) Board of Directors. Dr. Na...
News, Short Squeeze, Breakout and More Instantly...
Generex Biotechnology Company Name:
GNBT Stock Symbol:
OTCMKTS Market:
Generex Biotechnology Website:
MIRAMAR, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) subsidiary Olaregen Therapeutix announced in May that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Ge...
Ii-Key Immunotherapeutic Vaccine Technology Ii-Key-SARS-CoV-2 Vaccine Market Potential & International Contracts Market Potential for AE37 (Ii-Key-HER2) Immunotherapeutic Vaccine for breast, prostate, and bladder cancers MIRAMAR, Fla., June 22, 2021 (GLOBE NEWSWIRE) --...
NuGenHealth Software as a Service (SaaS) platform that enables their clients to monitor the health and wellbeing of their patient population. Westside Medicine & Cardiology, Inc. is a professional corporation that engages medical providers who are duly licensed in Ohio ...